The world’s first clinical trial on congenital deafness gene therapy showed that injecting a missing gene back into ear cells ...

The FDA has granted an accelerated approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy to treat patients ...

The US FDA has approved Otarmeni, a groundbreaking gene therapy by Regeneron, to restore natural hearing in children born ...

Maker says Otarmeni will be offered for free in the U.S.

The FDA has granted accelerated approval to Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy for pediatric and adult patients with OTOF-related sensorineural hearing loss.

US FDA approves Regeneron’s gene therapy, Otarmeni for genetic hearing loss: Tarrytown, New York Regeneron Pharmaceuticals, Inc., a leadi ...

A new gene therapy tested in China has improved the hearing of 38 people who were born deaf due to mutations in a gene called ...

The FDA has granted accelerated approval to lunsotogene parvec-cwha (Otarmeni), an adeno-associated virus (AAV) vector–based ...

Detailed price information for Envoy Medical Inc (COCH-Q) from The Globe and Mail including charting and trades.

Phonak, a global leader in innovative hearing solutions, today announced that its Virto R Infinio hearing aid has received ...

Envoy Medical Inc, a hearing health company pioneering fully implanted hearing solutions, announced that all 56 patients implanted and enrolled in its pivotal clinical trial evaluating the fully ...

Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of ...